Gilead's Loss in the Pulmonary Hypertension Drug Race Puts Pluristem and its Partner United Therapeutics Ahead of the Rest
(Thomson Reuters ONE) -
By Michael Morhamus, Contributor
Pulmonary arterial hypertension (PAH) is a chronic syndrome characterized by
abnormally high pressure in arteries leading from the heart to the lungs that
cause dizziness, fatigue, and shortness of breath.
Its cause is uncertain - some have blamed HIV, cocaine use, or the former diet
drug fen-phen. Incidence in the US is roughly 1,000 people per year; at any one
time, perhaps 30,000 are affected. Those with the disorder often go years
without a proper diagnosis until exercise capacity is significantly limited and
life expectancy greatly shortened. There is no cure, and current medications
leave something to be desired.
Pluristem Therapeutics' (NASDAQ:PSTI) platform technology of PLX cell therapy
may present a new and effective way to treat the disease. Last year, the company
struck a deal with United Therapeutics (UTHR), whose drugs for PAH comprise the
majority of United's revenue, to fund development. United's market presence with
compounds for PAH have been characterized by good sales growth, despite products
that carry a number of risks such as sepsis with its intravenous vasodilator and
an inhaler version of the same drug that underwent a brief recall when the
device caught fire. Clinical trials of a second generation drug have been
troubled.
The most recent blow in the pharmaceutical quest for a safe and effective drug
for PAH came last week when Gilead Sciences, Inc. (NASDAQ:GILD), with a
lackluster vasodilator tablet already on the market, halted development of
cicletanine after Phase II results showed no significant effect on an endpoint
of exercise. Other drug offerings for PAH have been neither unique or without
problems. GlaxoSmithKline's (NYSE:GSK) intravenous vasodilator Flolan has been
associated with blood infection and fatalities. Tracleer, a tablet released in
2001 by Actelion Ltd (SIX: ATLN)(PINK:ALIOF) that prevents blood vessels from
constricting, carries the potential for excessive bleeding and liver toxicity.
Pfizer, Inc. (NYSE:PFE) capitalizing on its Viagra success, released PDE5
inhibitor Revatio in 2006 and United Therapeutics followed three years later
with Adcirca, similar to Cialis made by Eli Lilly & Co. (LLY). Both, naturally,
carry the same risks as their sister drugs for erectile dysfunction. Sales
growth of commercially available compounds for PAH, however, has been very good,
with a worldwide market estimate of over $2.5 billion, based on sales of drugs
now on the market.
Gilead's absence should benefit Pluristem and United's efforts. Not only is a
better drug essential for this disease that carries up to a 30% mortality rate,
but United badly needs a new drug to keep, and expand, its PAH franchise. Keep
your eye on shares of PSTI as there appears to be considerable upside from here,
despite the fact that shares have vastly outperformed the over-all markets so
far this year. These developments have certainly put Pluristem and its Partner
United Therapeutics at the front- as leaders- in this Billion Dollar race.
The full report on PSTI and UTHR is available at:
http://www.biomedreports.com/20120828103170/gileads-loss-in-the-pulmonary-
hypertension-drug-race-puts-pluristem-and-its-partner-united-therapeutics-ahead-
of-the-rest.html
Healthcare investors and Biotech traders interested in accessing BioMedReports'
new complete database of clinical trials and upcoming FDA and world-wide
regulatory decisions which can be used to make more profitable trades and see
upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly
via twitter at: http://twitter.com/BioMedReports
####
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news
and the entire Healthcare Sector of the market. BioMedReports is not paid or
compensated to report the news and developments of publicly traded companies.
BioMedReports sells a premium product for subscribers and full disclosures and
information about the stocks and news mentioned in this news release is
available at BioMedReports.Com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioMedReports via Thomson Reuters ONE
[HUG#1636763]
Datum: 28.08.2012 - 16:53 Uhr
Sprache: Deutsch
News-ID 178345
Anzahl Zeichen: 5169
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Gilead's Loss in the Pulmonary Hypertension Drug Race Puts Pluristem and its Partner United Therapeutics Ahead of the Rest"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
